Evidence map›Paper›PMID 32597830›Full record

ArticleThe Journal of clinical investigation2020

Kv1.3 modulates neuroinflammation and neurodegeneration in Parkinson's disease.

Souvarish Sarkar, Hai M Nguyen, Emir Malovic, Jie Luo, Monica Langley, Bharathi N Palanisamy, Neeraj Singh, Sireesha Manne, Matthew Neal, Michelle Gabrielle and 14 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of clinical investigation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 1 pooled it
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 1 synthesis or guideline pooled it, 114 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Identification of Novel Kv1.3 Channel-Interacting Proteins Using Proximity Labelling in T-Cells.Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology · 2025
    Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 5 institutions in 2 countries.

Souvarish SarkarParkinson Disorders Research Laboratory, Department of Biomedical Sciences, Iowa State University (ISU), Ames, Iowa, USA.
Hai M NguyenDepartment of Pharmacology, School of Medicine, UCD, Davis, California, USA.
Emir MalovicParkinson Disorders Research Laboratory, Department of Biomedical Sciences, Iowa State University (ISU), Ames, Iowa, USA.
Jie LuoParkinson Disorders Research Laboratory, Department of Biomedical Sciences, Iowa State University (ISU), Ames, Iowa, USA.
Monica LangleyParkinson Disorders Research Laboratory, Department of Biomedical Sciences, Iowa State University (ISU), Ames, Iowa, USA.
Bharathi N PalanisamyParkinson Disorders Research Laboratory, Department of Biomedical Sciences, Iowa State University (ISU), Ames, Iowa, USA.
Neeraj SinghParkinson Disorders Research Laboratory, Department of Biomedical Sciences, Iowa State University (ISU), Ames, Iowa, USA.
Sireesha ManneParkinson Disorders Research Laboratory, Department of Biomedical Sciences, Iowa State University (ISU), Ames, Iowa, USA.
Matthew NealParkinson Disorders Research Laboratory, Department of Biomedical Sciences, Iowa State University (ISU), Ames, Iowa, USA.
Michelle GabrielleDepartment of Biochemistry, University of Western Ontario, London, Ontario, Canada.
Ahmed AbdallaParkinson Disorders Research Laboratory, Department of Biomedical Sciences, Iowa State University (ISU), Ames, Iowa, USA.
Poojya AnantharamDepartment of Veterinary Diagnostic and Production Animal Medicine, Veterinary Medicine Building, ISU, Ames, Iowa, USA.
Dharmin RokadParkinson Disorders Research Laboratory, Department of Biomedical Sciences, Iowa State University (ISU), Ames, Iowa, USA.
Nikhil PanickerParkinson Disorders Research Laboratory, Department of Biomedical Sciences, Iowa State University (ISU), Ames, Iowa, USA.
Vikrant SinghDepartment of Pharmacology, School of Medicine, UCD, Davis, California, USA.
Muhammet AyParkinson Disorders Research Laboratory, Department of Biomedical Sciences, Iowa State University (ISU), Ames, Iowa, USA.
Adhithiya CharliParkinson Disorders Research Laboratory, Department of Biomedical Sciences, Iowa State University (ISU), Ames, Iowa, USA.
Dilshan HarischandraParkinson Disorders Research Laboratory, Department of Biomedical Sciences, Iowa State University (ISU), Ames, Iowa, USA.
Lee-Way JinM.I.N.D. Institute, Alzheimer's Disease Center, Department of Pathology and Laboratory Medicine, UCD, Davis, California, USA.
Huajun JinParkinson Disorders Research Laboratory, Department of Biomedical Sciences, Iowa State University (ISU), Ames, Iowa, USA.
Srikant RangarajuDepartment of Neurology, Emory University School of Medicine, Atlanta, Georgia, USA.
Vellareddy AnantharamParkinson Disorders Research Laboratory, Department of Biomedical Sciences, Iowa State University (ISU), Ames, Iowa, USA.
Heike WulffDepartment of Pharmacology, School of Medicine, UCD, Davis, California, USA.
Anumantha G KanthasamyParkinson Disorders Research Laboratory, Department of Biomedical Sciences, Iowa State University (ISU), Ames, Iowa, USA.
Iowa State University · USUniversity of California, Davis · USAlzheimer’s Disease Neuroimaging Initiative · USEmory University · USWestern University · CA

Funding

UC Davis Alzheimer's Disease Core CenterP30AG010129 · NIA · UNIVERSITY OF CALIFORNIA DAVIS · PI MEYER, OANH L · 1991 to 2020
$28.3M
Targeting Kv1.3 potassium channels for neuro-immunomodulation in Alzheimer's DiseaseR01NS114130 · NINDS · YALE UNIVERSITY · PI RANGARAJU, SRIKANT · 2020 to 2024
$3.1M
Protein Aggregation and Inflammasome Signaling in Manganese Neurotoxicity.R01ES026892 · NIEHS · UNIVERSITY OF GEORGIA · PI KANTHASAMY, ANUMANTHA GOUNDER · 2016 to 2020
$2.0M
Neuroinflammation and microglial Kv1.3 in Parkinsons diseaseR01NS100090 · NINDS · UNIVERSITY OF GEORGIA · PI KANTHASAMY, ANUMANTHA GOUNDER · 2017 to 2021
$1.9M
Exosomes and Neuroinflammation in Parkinsons DiseaseR01NS088206 · NINDS · IOWA STATE UNIVERSITY · PI KANTHASAMY, ARTHI · 2015 to 2019
$1.6M
Microglial and macrophage potassium channels as regulators of neuroinflammation in Alzheimer's DiseaseK08NS099474 · NINDS · EMORY UNIVERSITY · PI RANGARAJU, SRIKANT · 2016 to 2020
$943k
NIA NIH HHS P30 AG010129NIEHS NIH HHS R01 ES026892NINDS NIH HHS K08 NS099474NINDS NIH HHS R01 NS088206NINDS NIH HHS R01 NS100090NINDS NIH HHS R01 NS114130
6 · The paper itself

Abstract

Characterization of the key cellular targets contributing to sustained microglial activation in neurodegenerative diseases, including Parkinson's disease (PD), and optimal modulation of these targets can provide potential treatments to halt disease progression. Here, we demonstrated that microglial Kv1.3, a voltage-gated potassium channel, was transcriptionally upregulated in response to aggregated α-synuclein (αSynAgg) stimulation in primary microglial cultures and animal models of PD, as well as in postmortem human PD brains. Patch-clamp electrophysiological studies confirmed that the observed Kv1.3 upregulation translated to increased Kv1.3 channel activity. The kinase Fyn, a risk factor for PD, modulated transcriptional upregulation and posttranslational modification of microglial Kv1.3. Multiple state-of-the-art analyses, including Duolink proximity ligation assay imaging, revealed that Fyn directly bound to Kv1.3 and posttranslationally modified its channel activity. Furthermore, we demonstrated the functional relevance of Kv1.3 in augmenting the neuroinflammatory response by using Kv1.3-KO primary microglia and the Kv1.3-specific small-molecule inhibitor PAP-1, thus highlighting the importance of Kv1.3 in neuroinflammation. Administration of PAP-1 significantly inhibited neurodegeneration and neuroinflammation in multiple animal models of PD. Collectively, our results imply that Fyn-dependent regulation of Kv1.3 channels plays an obligatory role in accentuating the neuroinflammatory response in PD and identify Kv1.3 as a potential therapeutic target for PD.

Indexed as

Protein Processing, Post-Translationalalpha-SynucleinAnimalsHumansInflammationKv1.3 Potassium ChannelMiceMice, KnockoutMicrogliaParkinson DiseaseProto-Oncogene Proteins c-fynalpha-SynucleinFYN protein, humanFyn protein, mouseKv1.3 Potassium ChannelProto-Oncogene Proteins c-fynSNCA protein, humanSnca protein, mouseInflammationNeurodegenerationNeuroscienceParkinson’s diseasePotassium channels

Identifiers

PMID32597830
PMCPMC7410064
OpenAlexW3037123232

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.